Affiliations: [a] Department of Emergency, The First Hospital of Jilin University, Changchun, Jilin, China | [b] Department of Gastrointestinal Medicine, The First Hospital of Jilin University, Changchun, Jilin, China
Correspondence:
[*]
Corresponding author: Xiang-Wei Meng, Department of Gastrointestinal Medicine, The First Hospital of Jilin University, 71 Xinmin Road, Changchun 130021, Jilin, China. Tel.: +86 0431 88782591; Fax: +86 043185654528; E-mail:xiangweimeng2003@163.com
Abstract: BACKGROUND: Matrix metalloproteinase 11 (MMP11) has been shown to play a key role in
human tumor progression and indicates poor clinical outcome in cancer
patients. OBJECTIVE: The current study aimed to evaluate the relationship between serum levels
of MMP-11 and prognosis in colon cancer patients. METHODS: Serum levels of MMP-11 were determined in 92 colon cancer patients and 92
healthy individuals using an enzyme-linked immunosorbent assay (ELISA).
Associations between serum MMP-11 levels and clinicopathological
characteristics of the patients and their outcomes were investigated.
Survival analyses were performed to measure the 5-year overall survival (OS)
and disease-free survival (DFS). RESULTS: Serum MMP-11 levels were substantially higher in colon cancer
patients than in healthy controls. Moreover, serum MMP-11 levels were
significantly higher in patients with advanced T status, lymph node
metastasis, distant metastasis, and a higher TNM stage. Elevated serum
levels of MMP-11 were identified as an independent prognostic factor for
5-year mortality and adverse events associated with colon cancer.
Multivariate Cox regression analysis identified the serum MMP-11 level as an
independent predictor of OS and DFS. CONCLUSION: Our study established that high serum levels of MMP-11 are associated with
poor clinical outcome and may serve as a prognostic biomarker in colon
cancer patients.
